- Home
- SIEB vs CRDL Comparison
SIEB vs CRDL Comparison
Compare SIEB & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIEB
- CRDL
- Stock Information
- Founded
- SIEB 1886
- CRDL 2017
- Country
- SIEB United States
- CRDL Canada
- Employees
- SIEB N/A
- CRDL N/A
- Industry
- SIEB Investment Bankers/Brokers/Service
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SIEB Finance
- CRDL Health Care
- Exchange
- SIEB Nasdaq
- CRDL Nasdaq
- Market Cap
- SIEB 95.1M
- CRDL 102.0M
- IPO Year
- SIEB N/A
- CRDL N/A
- Fundamental
- Price
- SIEB $2.97
- CRDL $0.93
- Analyst Decision
- SIEB
- CRDL Strong Buy
- Analyst Count
- SIEB 0
- CRDL 3
- Target Price
- SIEB N/A
- CRDL $9.00
- AVG Volume (30 Days)
- SIEB 17.5K
- CRDL 230.2K
- Earning Date
- SIEB 05-09-2025
- CRDL 05-13-2025
- Dividend Yield
- SIEB N/A
- CRDL N/A
- EPS Growth
- SIEB 57.14
- CRDL N/A
- EPS
- SIEB 0.33
- CRDL N/A
- Revenue
- SIEB $83,639,000.00
- CRDL N/A
- Revenue This Year
- SIEB N/A
- CRDL N/A
- Revenue Next Year
- SIEB N/A
- CRDL N/A
- P/E Ratio
- SIEB $9.12
- CRDL N/A
- Revenue Growth
- SIEB 17.39
- CRDL N/A
- 52 Week Low
- SIEB $1.41
- CRDL $0.88
- 52 Week High
- SIEB $3.34
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- SIEB 67.17
- CRDL 33.07
- Support Level
- SIEB $2.70
- CRDL $0.88
- Resistance Level
- SIEB $3.16
- CRDL $1.18
- Average True Range (ATR)
- SIEB 0.17
- CRDL 0.09
- MACD
- SIEB 0.07
- CRDL -0.02
- Stochastic Oscillator
- SIEB 77.38
- CRDL 15.00
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a holding company. It conducts retail discount brokerage business through its wholly-owned subsidiary. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.